Search results for "Phoma"

showing 10 items of 716 documents

Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma

2013

Abstract Altered expression of matricellular proteins can become pathogenic in the presence of persistent perturbations in tissue homeostasis. Here, we show that autoimmunity associated with Fas mutation was exacerbated and transitioned to lymphomagenesis in the absence of SPARC (secreted protein acidic rich in cysteine). The absence of SPARC resulted in defective collagen assembly, with uneven compartmentalization of lymphoid and myeloid populations within secondary lymphoid organs (SLO), and faulty delivery of inhibitory signals from the extracellular matrix. These conditions promoted aberrant interactions between neutrophil extracellular traps and CD5+ B cells, which underwent malignant …

MyeloidLymphoid Tissue: immunologyLymphomaNeutrophilsChronic lymphocytic leukemiaAutoimmunityOsteonectin: geneticsCHRONIC LYMPHOCYTIC-LEUKEMIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INHIBITORY RECEPTOR LAIR-1; KAPPA-B ACTIVATION; MARGINAL ZONE; INFLAMMATORY DISORDERS; MATRICELLULAR PROTEIN; SPARCMalignant transformationExtracellular matrixKAPPA-B ACTIVATIONLymphoma: immunologyMicehemic and lymphatic diseasesOsteonectinSYSTEMIC-LUPUS-ERYTHEMATOSUSNF-kappa B: immunologyCells CulturedTissue homeostasisB-LymphocytesCulturedNF-kappa BLymphoid Tissue: cytologyCell biologyCD5: immunologyExtracellular MatrixMutant Strainsmedicine.anatomical_structureINHIBITORY RECEPTOR LAIR-1OncologyCD95Stromal cellLymphoid TissueCellsBiologyCD95: geneticsCD5 AntigensINFLAMMATORY DISORDERSExtracellular Matrix: immunologymedicineAnimalsHumansfas ReceptorAntigensB-Lymphocytes: immunologyMATRICELLULAR PROTEINCHRONIC LYMPHOCYTIC-LEUKEMIASPARCLymphoma: geneticsNeutrophil extracellular trapsmedicine.diseaseAnimals; Antigens; Autoimmunity; B-Lymphocytes; B-Lymphocytes: immunology; CD5; CD5: immunology; CD95; CD95: genetics; Cells; Cultured; Extracellular Matrix; Extracellular Matrix: immunology; Humans; Lymphoid Tissue; Lymphoid Tissue: cytology; Lymphoid Tissue: immunology; Lymphoma; Lymphoma: genetics; Lymphoma: immunology; Mice; Mutant Strains; NF-kappa B; NF-kappa B: immunology; Neutrophils; Neutrophils: immunology; Osteonectin; Osteonectin: genetics; Osteonectin: immunologyMice Mutant StrainsCD5Neutrophils: immunologyOsteonectin: immunologyMARGINAL ZONELymphoma SPARC autoimmunityCD5
researchProduct

Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy

2016

Background The association of childhood leukemia with traffic pollution was considered in a number of studies from 1989 onwards, with results not entirely consistent and little information regarding subtypes. Aim of the study We used the data of the Italian SETIL case-control on childhood leukemia to explore the risk by leukemia subtypes associated to exposure to vehicular traffic. Methods We included in the analyses 648 cases of childhood leukemia (565 Acute lymphoblastic–ALL and 80 Acute non lymphoblastic-AnLL) and 980 controls. Information on traffic exposure was collected from questionnaire interviews and from the geocoding of house addresses, for all periods of life of the children. Re…

MyeloidMaleFuture studies010501 environmental sciencesSettore MED/42 - Igiene Generale E Applicata01 natural sciences0302 clinical medicineEconomicahemic and lymphatic diseasesMedicine030212 general & internal medicineChildRoad trafficacute non lymphoblastic leukemia; childhood; environment; leukemia; road traffic; air pollution; case-control studies; child; child preschool; female; humans; infant; Italy; leukemia myeloid acute; male; precursor cell lymphoblastic leukemia-lymphoma; risk; motor vehicles; medicine (all)LeukemiaTraffic pollutionMedicine (all)General MedicinePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemiaMotor VehiclesLeukemia Myeloid AcuteItalyAcute non Lymphoblastic LeukemiaSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICARoad TrafficChild PreschoolFemaleMedical emergencyCase-Control StudieHumanRiskChildhood leukemiaSocio-culturaleAcuteEnvironmentPrecursor Cell Lymphoblastic Leukemia Lymphoma03 medical and health sciencesEnvironmental healthAir PollutionHumansPreschool0105 earth and related environmental sciencesbusiness.industryCase-control studyType specificAmbientaleInfantmedicine.diseaseChildhoodCase-Control StudiesMotor Vehiclebusiness
researchProduct

T/NK “Nasal Type” Lymphomas: An Italian Cooperative Retrospective Survey.

2004

Abstract T/NK “nasal type” lymphoma is a neoplasm that shows a peculiar geographical distribution. In fact most of the reported cases come from Far Eastern countries such as Hong Kong, and Central America, particularly from Mexico; this kind of lymphoma occurrs rarely in western countries. Between 1997 and 2004, 19 new cases of T/NK nasal type lymphoma were diagnosed in 7 Italian Hematology Division. Patients characteristics were as follows: all caucasian; 14 men and 5 women; median age 53 years (range 20–80). The presentation at the onset was in the nasal cavity or adjacent structures in 15 cases, who presented symptoms like nasal obstruction, dysphagia, orbital edema; in 2 cases, skin les…

Nasal cavitymedicine.medical_specialtyChemotherapyHematologymedicine.diagnostic_testCyclophosphamidebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryLymphomaSurgerymedicine.anatomical_structureInternal medicineBiopsymedicineStage (cooking)medicine.symptombusinessBone painmedicine.drugBlood
researchProduct

Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte Telomere Length

2020

Leukocyte telomere length (LTL) is a heritable biomarker of genomic aging. In this study, we perform a genome-wide meta-analysis of LTL by pooling densely genotyped and imputed association results across large-scale European-descent studies including up to 78,592 individuals. We identify 49 genomic regions at a false dicovery rate (FDR) < 0.05 threshold and prioritize genes at 31, with five highlighting nucleotide metabolism as an important regulator of LTL. We report six genome-wide significant loci in or near SENP7, MOB1B, CARMIL1, PRRC2A, TERF2, and RFWD3, and our results support recently identified PARP1, POT1, ATM, and MPHOSPH6 loci. Phenome-wide analyses in >350,000 UK Biobank p…

Netherlands Twin Register (NTR)LimfomesLOCIGenome-wide association studyDiseaseVARIANTSDISEASE0302 clinical medicineLeukocytestelomere lengthGWASGenetics(clinical)CàncerMendelian randomisationThyroid cancerGenetics (clinical)11 Medical and Health SciencesCancerGeneticsGenetics & HeredityRISK0303 health sciencesTelòmerage-related disease; biological aging; Mendelian randomisation; telomere length; Humans; Leukocytes; Nucleotides; Genome-Wide Association Study; TelomereNucleotidesmeta-analyysigenomiikkaGenomicsTelomereCANCER3. Good health030220 oncology & carcinogenesisbiological agingMENDELIAN RANDOMIZATION/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMedical geneticsBiomarker (medicine)HEARTLymphomasLife Sciences & BiomedicineMedical Geneticsmedicine.medical_specialtyGENESDATABASEAge-related Disease ; Biological Aging ; Mendelian Randomisation ; Telomere LengthBiologyArticle03 medical and health sciencesSDG 3 - Good Health and Well-beingMendelian randomization/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_medicineGeneticsJournal ArticleHumans030304 developmental biologyMedicinsk genetikage-related diseaseScience & TechnologyCancer06 Biological Sciencesmedicine.diseaseTelomereGenòmicaikääntyminen1182 Biochemistry cell and molecular biologytelomeeritbiologicalGenome-Wide Association Study
researchProduct

ChemInform Abstract: Synthesis and Antineoplastic Activity of New 4-Diazopyrazole Derivatives.

2010

Several new 4-diazopyrazole derivatives were synthesized by reaction of 1-(R-substituted)phenyl-3-methyl-5-benzamidopyrazoles with a sevenfold excess of nitrous acid in acetic media. The compounds were tested at 20 microM concentration for their antineoplastic activity in vitro against Raji (human Burkitt lymphoma), K562 (human chronic myelogenous leukemia) and U937 (human histiocytic lymphoma) cell lines. They showed a percent of growth inhibition in the range 23.4-100%.

Nitrous acidChemistryHistiocytic lymphomaStereochemistryGeneral Medicinemedicine.diseaseMolecular biologyIn vitroLymphomachemistry.chemical_compoundCell culturehemic and lymphatic diseasesmedicineGrowth inhibitionChronic myelogenous leukemiaK562 cellsChemInform
researchProduct

Comparative Antiproliferative and Antiangiogenic Activity of Cacao Preparations (P06-048-19)

2019

OBJECTIVES: Multiple lines of evidence show the benefits of cacao on inflammation and cardiovascular disease. The relationship between cacao and cancer is less well defined. Cacao contains bioactive compounds with antiangiogenic properties, such as procyanidins and catechins. Angiogenesis, blood vessel formation, is critical for tumor growth and validated target in cancer therapy. We studied the antiangiogenic and anti-tumorigenic potential of two commercially available 100% cacaos (Valrhona and De Zaan). METHODS: L5178y mouse lymphoma cells were incubated with different concentrations of cacao (0, 0.1, 0.3, 1, 3, and 10 µl/ml). The calorimetric methylthiazolyldiphenyl-tetrazolium bromide (…

Nutrition and Dieteticsbusiness.industryAngiogenesisCancer therapyMedicine (miscellaneous)CancerInflammationDietary Bioactive ComponentsDiseasemedicine.diseaseUmbilical veinLymphomamedicine.anatomical_structureCancer researchmedicinemedicine.symptombusinessFood ScienceBlood vessel
researchProduct

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

2021

Abstract Introduction The CD19 targeting CAR-T cell constructs axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have become an accepted standard salvage treatment of LBCL beyond the second line. Patients scheduled for approved CAR-T cell therapies usually have 4-8 weeks wait time for CAR-T cell infusion, thus often requiring bridging strategies in rapidly progressing patients to achieve disease control until start of lymphodepletion. It is still unclear, however, if the adverse impact of active progressive lymphoma can be overcome by successful bridging. We have addressed this question using registry data provided by the German Registry for Stem Cell Transplantation (DRST),…

Oncology0303 health sciencesmedicine.medical_specialtyStandard of careBridging (networking)business.industryImmunologyCell BiologyHematologymedicine.diseaseBiochemistrylanguage.human_language3. Good healthGerman03 medical and health sciences0302 clinical medicineInternal medicinelanguagemedicineCAR T-cell therapybusinessB-cell lymphoma030304 developmental biology030215 immunologyBlood
researchProduct

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: resul…

2013

Purpose Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20+/CD22+ B-cell non-Hodgkin lymphoma (NHL). Patients and Methods A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NH…

OncologyAdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentFollicular lymphomaPharmacologyAntibodies Monoclonal HumanizedDrug Administration Schedulechemistry.chemical_compoundAntibodies Monoclonal Murine-Derivedimmune system diseasesRecurrenceRisk Factorshemic and lymphatic diseasesInternal medicineCalicheamicinAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInotuzumab OzogamicinMolecular Targeted TherapyB-cell lymphomaAgedHyperbilirubinemiaInotuzumab ozogamicinChemotherapybusiness.industryLymphoma Non-HodgkinMiddle Agedmedicine.diseasePrognosisThrombocytopeniaPolatuzumab vedotinLymphomaTreatment OutcomeOncologychemistryLiverRituximabFemalebusinessRituximabLiver Failuremedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.

2012

Long-term population-based survival data detailed by cancer subtype are important to measure the overall outcomes of malignancy managements. We provide net survival estimates at 1, 3, 5 and 10-year postdiagnosis on 37,549 hematological malignancy (HM) patients whose ages were >15 years, diagnosed between 1989 and 2004 and actively followed until 2008 by French population-based cancer registries. These are, to our knowledge, the first unbiased estimates of 10-year net survival in HMs detailed by subtypes. HMs were classified according to the International Classification of Diseases-Oncology 3. Net survival was estimated with the unbiased Pohar-Perme method. The results are reported by sex an…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationFollicular lymphomaMalignancyAge DistributionBiasInternal medicinemedicineHumansRegistriesSex DistributioneducationAgededucation.field_of_studyLeukemiaModels Statisticalbusiness.industryMortality rateLymphoma Non-HodgkinCancerMiddle Agedmedicine.diseasePrognosisHodgkin DiseaseLymphomaCancer registryOncologyHematologic NeoplasmsMyelodysplastic SyndromesImmunologyFemaleFrancebusinessChronic myelogenous leukemiaInternational journal of cancer
researchProduct

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mant…

2017

Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the R…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLymphoma Mantle-CellMalignancy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryQuality of lifePiperidinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineDisease burdenAgedNeoplasm StagingAged 80 and overSirolimusbusiness.industryAdenineCancerHematologyMiddle Agedmedicine.diseaseTemsirolimusSurgeryPyrimidinesTreatment OutcomeOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisIbrutinibRetreatmentQuality of LifePyrazolesMantle cell lymphomaFemalebusinessmedicine.drug
researchProduct